Sanofi's Adjuvant Produces a High Immune Response at Low Dose - - BioPharm International

ADVERTISEMENT

Sanofi's Adjuvant Produces a High Immune Response at Low Dose

BioPharm Bulletin

Sanofi Pasteur (Lyon, France) has produced data showing that its new investigational H5N1 pandemic influenza vaccine containing a proprietary adjuvant achieved a high immune response at the lowest dose of H5N1 antigen reported to date.

The vaccine containing 1.9 micrograms of antigen generated a high level of seroprotective immune response in over 70% of the participants in a clinical trial and, in the same clinical trial, vaccine containing 3.75 micrograms of antigen generated a high level of seroprotective immune response in over 80% of the participants. Further assessment of the vaccine is ongoing.

Sanofi Pasteur release

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm Bulletin,
Click here